Rocketvax and Basel University therapy uses a modified coronavirus that activates an immune response
Rocketvax and Basel University therapy uses a modified coronavirus that activates an immune response
The structure of NanoBone triggers bone-forming systems while also aiding rapid bone healing
Company’s phase 3 study showed treatment with Tagrisso reduced risk of death by over half
New division aims to provide laboratories with the equipment and support to uphold analytical data
BI-1910 is now the second of the company’s anti-tumour necrosis factor receptor 2 programmes to enter clinical development
The final draft guidance recommends rimegepant for adults who have at least four migraine attacks per month, but less than 15
Nitisinone capsules are indicated for patients with hereditary tyrosinemia type 1 in combination with dietary restriction of tyrosine and phenylalanine
Synaffix’s technology platform is intended to enhance and extend Lonza’s integrated ADC services
The neurological disease affects approximately 2.8 million people worldwide
The inflammatory form of arthritis is estimated to affect nearly 38 million people worldwide
The EMA’s human medicines committee concluded that the benefits of Adakveo did not outweigh its risks
The drug has already been approved for this indication in the EU, with regulatory reviews continuing elsewhere including in the US
Therapy has been developed for use among children and adolescents with growth hormone deficiency
Life Sciences Council meeting hosted by chancellor Jeremy Hunt has unfolded in Downing Street
The collaboration aims to develop novel preclinical models with a view to identifying new treatments